Trial Profile

OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects With Neovascular Age-Related Macular Degeneration (AMD)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 04 Apr 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 May 2018 According to Vitrisa Therapeutics media release, company will share the results of sub-analyses of this study with the retina community at future scientific meetings.
14 Feb 2018 Status changed from active, no longer recruiting to discontinued company has discontinued further development of squalamine to preserve cash and to evaluatie strategic alternatives to maximize shareholder value, according to an Ohr Pharmaceutical media release.
05 Jan 2018 Results presented in an Ohr Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com